Form 4: Edwards Lifesciences Executive Equity Grant Disclosure

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, received restricted stock units and stock options as part of the company's long-term incentive program.

Summary

• Daniel J. Lippis, CVP of TAVR, was granted 7,850 restricted stock units (RSUs) on May 7, 2026.
• The executive received an option grant for 39,900 shares of common stock with an exercise price of $82.76.
• A total of 759 shares were withheld to cover tax obligations related to the vesting of equity awards.
• The reporting person's total beneficial ownership following these transactions is 40,772.9103 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which carries a neutral sentiment regarding the company's operational performance.

Positives

• Equity grants align executive interests with long-term shareholder value creation.
• The inclusion of performance-based restricted stock units (up to 200% of target) incentivizes achievement of specific corporate goals.

Negatives

• The transaction involved the withholding of shares to satisfy tax obligations, which is a standard but routine reduction in direct holdings.

Risks

• Vesting of performance-based units is contingent upon achieving specific performance goals over a three-year period.
• Market volatility may impact the future value of the granted stock options and RSUs.

Future Outlook

The executive's compensation is tied to a three-year performance period ending in 2029, with vesting schedules extending over four years for standard grants.

Management Comments

• The grants are issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation practices within the medical device sector, where long-term equity incentives are used to retain key leadership in the competitive TAVR (Transcatheter Aortic Valve Replacement) market.

Comparison to Industry Standards

• The use of four-year vesting schedules for stock options is consistent with standard corporate governance practices for large-cap medical device companies like Medtronic or Boston Scientific.
• Performance-based equity awards are a standard industry benchmark for aligning executive compensation with long-term operational success.

Stakeholder Impact

• Shareholders should note the dilution impact of new equity grants, though these are standard components of executive retention packages.

Next Steps

• Vesting of initial tranches of equity grants beginning May 7, 2027.
• Performance evaluation for performance-based units over the three-year period ending May 2029.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Equity Compensation, TAVR